ea0090ep1163 | Late Breaking | ECE2023
Ehrenwald Michal
, Kolitz Tamara
, Karov Ruth
, Brenner Ronen
, Greenman Yona
Background: Immune checkpoint inhibitors (ICPIs) are indicated as treatment for metastatic renal cell carcinoma (RCC) and melanoma, among other malignancies. This group of agents is associated with immune-related adverse events (irAEs). We aimed to further investigate the association of immune-related thyroid disorders (irTDs) with clinical outcomes and mortality rates in patients with RCC or melanoma who were treated with ICPIs.Methods: We retrospective...